Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Natera, Inc.
< Previous
1
2
Next >
Natera Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 06, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Report its Second Quarter 2024 Results on August 8, 2024
July 30, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
July 26, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
July 03, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
June 27, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
June 17, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
May 30, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
May 23, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
May 23, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Reports First Quarter 2024 Financial Results
May 09, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
May 03, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Report its First Quarter 2024 Results on May 9
May 01, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
May 01, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
April 22, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
April 11, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
April 08, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
April 05, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
April 01, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
March 18, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
March 14, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
March 12, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
March 07, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera to Participate in March Investor Conferences
February 29, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
February 27, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
February 26, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
February 20, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
New Study Validates Signatera™ in Endometrial Cancer
February 05, 2024
From
Natera, Inc.
Via
Business Wire
Tickers
NTRA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.